Fiche publication
Date publication
avril 2016
Journal
Journal of the American Society of Hypertension : JASH
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Sag AA, Sos TA, Benli C, Sal O, Rossignol P, Ortiz A, Solak Y, Kanbay M
Lien Pubmed
Résumé
Unlike endovascular therapeutic studies for atherosclerosis in many other vascular beds, major trials regarding endovascular renovascular revascularization have resulted in a stagnating equipoise. However, every major trial completed for this topic thus far has suffered from major methodological flaws that limit the validity and external generalizability of their results. Furthermore, certain patient populations who are known to benefit from renovascular revascularization may never be studied because they cannot be ethically withheld from life-saving treatment. Forthcoming percutaneous techniques may one day complement angioplasty and stenting in a burgeoning era of cellular modulation and endovascular-directed renal regeneration.
Mots clés
Angioplasty, instrumentation, Atherosclerosis, complications, Drug-Eluting Stents, trends, Endovascular Procedures, methods, Evidence-Based Medicine, methods, Humans, Hypertension, Renovascular, diagnostic imaging, Kidney, diagnostic imaging, Magnetic Resonance Imaging, Nephrons, surgery, Parenchymal Tissue, diagnostic imaging, Patient Selection, Randomized Controlled Trials as Topic, Renal Artery Obstruction, diagnostic imaging
Référence
J Am Soc Hypertens. 2016 Apr;10(4):368-77
